On June 16, 2024, Pharm&Access LLP has signed an exclusive distribution agreement with CHIESI FARMACEUTICI S.p.A., an Italian biopharmaceutical company, for the sale of several orphan drugs: LOJUXTA®, FILSUVEZ GEL®, LAMZEDE®, MYALEPTA®, Elfabrio®, Procysbi®, Raxone®, Ferriprox® in Kazakhstan.

Pharm&Access LLP strives to provide access to therapy for patients with rare diseases in Kazakhstan and Central Asia. This agreement with CHIESI FARMACEUTICI will provide new opportunities not only for patients with rare diseases but also for doctors who are involved in the diagnostics and treatment of orphan diseases in the Republic of Kazakhstan.

#rarediseasecompanykazakhstan #businessdevelopmentinkazakhstan #CentralAsia #ChiesiFarmaceutici #orphandiseasepatientsinKazakhstan #orphanpharmaceuticalcompanyinKazakhstan #rarediseasepatientsinCentralAsia #orphanpharmacompany